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osting by EAbstract We describe a case of signiﬁcant regression of aggressive, deep and superﬁcial corneal
vascularization using photodynamic therapy (PDT) with verteporﬁn, repeated subconjunctival
injections of Avastin, plus topical cyclosporin-A 1% drops.
The area of the corneal vascularization was treated with PDT with verteporﬁn. The subconjunc-
tival space – next to the area of vascularization – was injected with Avastin (1.25 mg/0.05 ml),
immediately after PDT, and then for two more times during the follow-up period. The patient
was kept on topical cyclosporin and prednisolone acetate. The outcome was evaluated clinically
and photographically for 13 months. Corneal vascularization regressed signiﬁcantly. No adverse
effects were observed, neither locally or systemically. PDT with verteporﬁn, repeated subconjunc-
tival injections of Avastin, and topical cyclosporin-A drops appear to be safe and effective in treat-
ing aggressive corneal vascularization.
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lsevier1. Introduction
Corneal vascularization is a serious complication that can com-
plicate inﬂammatory or infectious diseases of the ocular surface.
Corneal vascularization can lead to chronic inﬂammation, cor-
neal scarring, lipid keratopathy and corneal edema. It is consid-
ered as a signiﬁcant risk factor for corneal graft rejection after
penetrating keratoplasty (Dua and Azuara-Blanco, 1999).
Many methods have been tried to treat corneal vasculariza-
tion however the success rate was variable. These methods in-
clude; argon laser photocoagulation (Mendelsohn et al., 1986),
Figure 2 Another view of the corneal vascularization showing
the depth of the vascular tree.
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et al., 2003; Yoon et al., 2007), ﬁne needle diathermy (Pillai
et al., 2000), topical, subconjunctival, intracorneal Avastin
injections (Regenfuss et al., 2009; Vassileva and Hergeldzhi-
eva, 2009) and beta ray therapy (Vassileva and Hergeldzhieva,
2009; Mailath and Peter, 1972).
We report a case of signiﬁcant regression of aggressive,
deep and superﬁcial corneal vascularization after photody-
namic therapy (PDT) with verteporﬁn, repeated subconjuncti-
val injections of Avastin and topical cyclosporin-A drops. To
the best of our knowledge, this is the ﬁrst time to combine cor-
neal photodynamic therapy (PDT) using verteporﬁn with sub-
conjunctival Avastin injections and topical cyclosporin drops
to treat corneal vascularization.
2. Case report
A 77-year-old male was referred to the Anterior Segment
Clinic with severely vascularized, and decompensated cornea,
aphakia and uncontrolled glaucoma in his only eye after a
complicated cataract surgery done elsewhere many months
ago. The patient lost the other eye a long time ago because
of trauma.
On examination, uncorrected visual acuity (UCVA) in the
right eye was hand movement in front of the face with no
improvement with pinhole; due to the poor view, no refraction
could be obtained. Visual acuity in the left eye was no light
perception. The intraocular pressure (IOP) in the right eye
was 20 mmHg, and the patient was not on anti-glaucoma
medications. Slit lamp examination of the right eye showed a
moderate circumcorneal ﬂush, healed superior corneal cataract
incision with multiple pointing old sutures, sever corneal
edema with multiple areas of aggressive deep and superﬁcial
corneal vascularization – mainly between 9 and 10 o’clock po-
sition as shown in Figs. 1 and 2. The central cornea had large
areas of climatic droplet keratopathy, and scarring. Examina-
tion of the anterior chamber (AC) was very difﬁcult because of
the state of the cornea, but no intraocular lens (IOL) could be
seen. There was an area of broad superior peripheral anterior
synechiae, the red reﬂex was faint. Diagnostic ultrasound
showed a normal posterior pole.
It was decided to treat the corneal vascularization before
scheduling the patient for penetrating keratoplasty (PKP),Figure 1 Preoperative appearance of the right cornea showing
localized aggressive corneal vascularization.release of the peripheral anterior synechiae and insertion of a
secondary posterior chamber intraocular lens as the graft will
have a better chance of survival after occluding the corneal
blood vessels. An informed consent was obtained and the
whole treatment plan was explained to the patient.
PDT with verteporﬁn (Visudyne, Novartis Ophthamics
AG, Hettingen Switzerland) was used as described in the liter-
ature (Fossarello et al., 2003) to treat the corneal blood vessels.
Five consecutive and overlapping 3.5 mm spots were adminis-
tered. After completing the treatment, a 1.25 mg/0.05 ml of
Avastin was injected in the subconjunctival space. The
patient was started on topical prednisolone acetate drops
1%, and topical cyclosporin-A 1% four times a day. After
2 weeks, the area of the treated corneal vascularization showed
deep intrastomal hemorrhages, obscuring the view to the deep
layers of the cornea. The superﬁcial corneal layers showed
residual markedly attenuated blood vessels, as shown in
Fig. 3. Another injection of subconjunctival Avastin was gi-
ven to the patient and he was instructed to continue on the
same medications. On examining the patient after 6 weeks,
we found that there was a dramatic regression of the corneal
vascularization with only a small non-signiﬁcant twig of super-
ﬁcial vascularization attracted to an area of a broken old
suture (see Fig. 4). A third injection of subconjuctival AvstinFigure 3 Deep intrastromal hemorrhages at the site of the
corneal vascularization – 2 weeks after the treatment.
Figure 4 Dramatic regression of the corneal blood vessels –
8 weeks after the initial treatment.
Figure 5 Appearance of the right eye four months after the
scleral ﬁxation intraocular lens, anterior vitrectomy, release of
peripheral synechiae, penetrating keratoplasty subconjunctival
and intracameral.
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ment. Six months after the PDT, the patient underwent
uneventful penetrating keratoplasty, anterior vitrectomy, re-
lease of synechia, insertion of a scleral ﬁxation intraocular lens,
plus subconjunctival and intracameral (1.25 mg/0.05 ml) Ava-
stin injection. Fig. 5 shows the appearance of the cornea
4 months after the keratoplasty. In his last follow-up
13 months after the PDT, the patient remained stable with
no signiﬁcant vessels developing.
3. Discussion
The success of treating corneal vascularization depends on the
extent, the duration of the abnormal vessels, as well as on the
mode of treatment. Aggressive vascularization is difﬁcult to
eradicate completely, and usually needs more than one mode
of treatment. Despite that, recurrence of the vascularization
is high. On the other hand, choosing the mode of treatment
is determined by the cost, availability and the possible side
effects.
Our patient had a long standing corneal vascularization,
therefore we anticipated that the majority of those vessels werealready mature, and hence we expected a low level of Vascular
Endothelial Growth Factor (VEGF), as compared to fresh, ac-
tively growing vascularization. And based on that, we expected
a suboptimum response to anti-VEGF alone. Considering the
size of the vessels and their extent we decided that PDT with
verteporﬁn is a better choice, as there will be a high chance
of getting good concentration of verteporﬁn in this huge
vascular network, and hence more effect. In contrast to vascu-
lar networks with sluggish circulation or ghost vessels were
vertiporﬁn concentration is expected to be low resulting
in minimal or no effect (clinical experience with other
patients).
It is well established that one of the major problems, when
dealing with corneal vascularization, is their tendency to recur
after treatment. Most of the treatment methods may occlude
the blood vessels, but do not adequately suppress the postop-
erative inﬂammation, or the process of angiogenesis that fol-
lows these procedures as a normal healing process of the
injured blood vessels, and result in recurrence of the same
problem. We believe that in order to successfully eradicate cor-
neal or any other pathological vascularization certain consid-
eration should be addressed; the structure of the abnormal
blood vessels should be destroyed, then the recurrence should
be prevented by treating the aetiology of the vascularization
and suppressing the subsequent neovascularization that occurs
as a normal healing process of the injured blood vessels. In our
patient, PDT with verteporﬁn was used to destroy the abnor-
mal blood vessels, while repeated subsequent subconjunctival
Avastin injections, topical cyclosporin A and topical steroids
were used to control the postoperative inﬂammation and to
prevent the process of angiogenesis. And replacing the decom-
pensated cornea will help in removing the major inciting etiol-
ogy for this vascularization. The currently recommended
concentration for subconjunctival or intrastromal injections
of Avastin is 2.5 mg/0.1 ml (Regenfuss et al., 2009; Vassileva
and Hergeldzhieva, 2009), however when we injected our pa-
tient there were no data regarding the recommended dose,
and we had to start with a low dose, accepting the very high
possibility of suboptimum dose. Topical Avastin in different
concentrations and dosing regimens is another mode of deliv-
ering anti-VEGF to treat corneal vascularization (Koenig
et al., 2009), primary and recurrent pterygium (Teng et al.,
2009; Fallah et al., 2010). This method appears to be promising
as it provides continuous supply of the anti-VEGF to the area
of vascularization. In contrast to the short-term effect of the
local injections, however introducing a method of delivery that
provides a longer time of contact between the drug and the
ocular surface, e.g., sustained release preparations (Lim
et al., 2009), may further improve the outcome.
The anti-angiogenic effect of cyclosporin A (Benelli et al.,
1997; Herna´ndez et al., 2001) and topical steroids (McNatt
et al., 1999; Boneham and Collin, 1995) have also been demon-
strated, Combining these two medications with subconjuncti-
val Avastin and PDT with verteporfen appeared to be
effective in regressing and preventing the recurrence of aggres-
sive corneal vascularization with no obvious complications in
this particular patient. However, more studies need to be done
to conﬁrm this ﬁnding.
In conclusion, the combined use of PDT with verteporﬁn,
subconjunctival Avastin injections, topical cyclosprin A,
and steroid drops appear to be effective in treating and
preventing the recurrence of aggressive corneal vascularization
154 O.M. Kirat, H.A. Al-Dhibiwith no observed complications, to our knowledge this is the
ﬁrst reported case to combine these treatment modes in treat-
ing aggressive corneal vascularization.
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